Loading...
XKRX207940
Market cap46bUSD
Dec 20, Last price  
939,000.00KRW
1D
-1.98%
1Q
-11.42%
Jan 2017
521.85%
IPO
481.42%
Name

Samsung Biologics Co Ltd

Chart & Performance

D1W1MN
XKRX:207940 chart
P/E
77.92
P/S
18.09
EPS
12,050.63
Div Yield, %
0.00%
Shrs. gr., 5y
1.26%
Rev. gr., 5y
47.13%
Revenues
3.69t
+23.10%
105,148,783,57091,278,028,790294,622,020,770464,629,334,140535,805,801,070701,591,859,7601,164,776,873,6401,568,006,928,0403,001,295,197,6803,694,588,767,060
Net income
857.69b
+7.47%
-95,909,287,8101,904,945,916,600-176,823,409,530-96,972,115,810224,109,194,870202,904,099,090240,974,799,960393,589,467,650798,056,210,080857,691,298,380
CFO
1.67t
+74.83%
-108,299,232,940-265,513,751,570-62,661,298,030149,816,327,600-32,417,327,33010,153,614,980202,090,026,540454,596,217,270953,047,810,0801,666,228,521,440
Earnings
Jan 22, 2025

Profile

Samsung Biologics Co.,Ltd. engages in the contract manufacturing organization (CMO) business for biopharmaceuticals products. The company operates in two segments, CMO and Contract Development Organization (CDO). It is involved in the provision of CDO services, including cell line development, upstream and downstream processes, and analytical methods and formulations. The company also offers aseptic filling, lyophilization, finishing, storage and shipping, and support services; and quality assurance and control, as well as biosafety and analytical testing services. In addition, it engages in the development and commercialization of biosimilar drugs; and manufactures mammalian cell-based antibody drugs. The company was founded in 2011 and is headquartered in Incheon, South Korea.
URL
https://samsungbiologics.com/
IPO date
Nov 10, 2016
Employees
Domiciled in
KR
Incorporated in
KR

Valuation

Title
KRW in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑122014‑12
Income
Revenues
3,694,588,767
23.10%
3,001,295,198
91.41%
1,568,006,928
34.62%
Cost of revenue
2,285,202,032
1,788,220,999
1,020,520,290
Unusual Expense (Income)
NOPBT
1,409,386,735
1,213,074,199
547,486,638
NOPBT Margin
38.15%
40.42%
34.92%
Operating Taxes
262,295,633
210,968,364
167,693,130
Tax Rate
18.61%
17.39%
30.63%
NOPAT
1,147,091,102
1,002,105,835
379,793,509
Net income
857,691,298
7.47%
798,056,210
102.76%
393,589,468
63.33%
Dividends
Dividend yield
Proceeds from repurchase of equity
3,200,751,000
BB yield
-5.58%
Debt
Debt current
1,531,935,793
1,281,047,076
167,392,132
Long-term debt
659,041,798
1,643,128,450
1,143,563,461
Deferred revenue
394,731,924
249,394,488
Other long-term liabilities
1,680,447,195
574,100,860
9,152,703
Net debt
87,266,424
1,958,494,868
(1,428,965,119)
Cash flow
Cash from operating activities
1,666,228,521
953,047,810
454,596,217
CAPEX
(995,070,662)
(1,009,225,611)
(421,151,826)
Cash from investing activities
(1,566,305,450)
(3,106,477,133)
(933,489,191)
Cash from financing activities
(635,049,948)
3,000,080,260
496,622,136
FCF
8,745,810
(493,446,232)
(91,569,803)
Balance
Cash
2,056,275,689
3,193,537,267
1,371,435,206
Long term investments
47,435,477
(2,227,856,608)
1,368,485,506
Excess cash
1,918,981,728
815,615,899
2,661,520,365
Stockholders' equity
4,181,427,801
3,323,536,436
2,512,599,697
Invested Capital
11,501,290,457
11,428,425,542
3,919,622,628
ROIC
10.01%
13.06%
10.32%
ROCE
10.50%
9.01%
7.91%
EV
Common stock shares outstanding
71,174
69,810
66,867
Price
760,000.00
-7.43%
821,000.00
-8.00%
892,431.00
8.04%
Market cap
54,092,240,000
-5.62%
57,313,741,533
-3.96%
59,674,517,446
8.04%
EV
54,179,706,491
59,274,409,795
58,254,362,966
EBITDA
1,899,168,730
1,521,338,520
709,275,288
EV/EBITDA
28.53
38.96
82.13
Interest
81,596,401
64,064,346
14,707,182
Interest/NOPBT
5.79%
5.28%
2.69%